KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Invested Capital (2016 - 2025)

Neogenomics' Invested Capital history spans 16 years, with the latest figure at $836.6 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 7.29% year-over-year to $836.6 million; the TTM value through Dec 2025 reached $836.6 million, down 7.29%, while the annual FY2025 figure was $836.6 million, 7.29% down from the prior year.
  • Invested Capital reached $836.6 million in Q4 2025 per NEO's latest filing, roughly flat from $838.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.1 billion in Q2 2021 to a low of $836.6 million in Q4 2025.
  • Average Invested Capital over 5 years is $962.7 million, with a median of $944.5 million recorded in 2023.
  • Peak YoY movement for Invested Capital: soared 75.53% in 2021, then fell 10.93% in 2022.
  • A 5-year view of Invested Capital shows it stood at $1.1 billion in 2021, then decreased by 9.95% to $998.0 million in 2022, then dropped by 5.66% to $941.5 million in 2023, then dropped by 4.16% to $902.3 million in 2024, then fell by 7.29% to $836.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Invested Capital are $836.6 million (Q4 2025), $838.3 million (Q3 2025), and $854.0 million (Q2 2025).